Evidence map›Paper›PMID 39130515›Full record

ArticleBrain communications2024

James H Catterson, Edmond N Mouofo, Inés López De Toledo Soler, Gillian Lean, Stella Dlamini, Phoebe Liddell, Graham Voong, Taxiarchis Katsinelos, Yu-Chun Wang, Nils Schoovaerts and 3 more

Abstract read
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

James H CattersonCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.
Edmond N MouofoCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.
Inés López De Toledo SolerCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.
Gillian LeanCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.
Stella DlaminiCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.
Phoebe LiddellCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.
Graham VoongCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.
Taxiarchis KatsinelosSchaller Research Group at the University of Heidelberg and the DKFZ, German Cancer Research Center, Proteostasis in Neurodegenerative Disease (B180), INF 581, 69120 Heidelberg, Germany.
Yu-Chun WangVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, 3000 Leuven, Belgium.
Nils SchoovaertsVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, 3000 Leuven, Belgium.
Patrik VerstrekenVIB-KU Leuven Center for Brain & Disease Research, Department of Neurosciences, 3000 Leuven, Belgium.ORCID https://orcid.org/0000-0002-5073-5393
Tara L Spires-JonesCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID https://orcid.org/0000-0003-2530-0598
Claire S DurrantCentre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh EH8 9XD, UK.ORCID https://orcid.org/0000-0001-7552-7358

Funding

Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
NIH HHS P40 OD018537
6 · The paper itself

Abstract

Alzheimer's disease is the most common cause of dementia in the elderly, prompting extensive efforts to pinpoint novel therapeutic targets for effective intervention. Among the hallmark features of Alzheimer's disease is the development of neurofibrillary tangles comprised of hyperphosphorylated tau protein, whose progressive spread throughout the brain is associated with neuronal death. Trans-synaptic propagation of tau has been observed in mouse models, and indirect evidence for tau spread via synapses has been observed in human Alzheimer's disease. Halting tau propagation is a promising therapeutic target for Alzheimer's disease; thus, a scalable model system to screen for modifiers of tau spread would be very useful for the field. To this end, we sought to emulate the trans-synaptic spread of human tau in

Indexed as

Alzheimer’s diseaseDrosophila melanogasterneurodegenerationtautrans-synaptic

Identifiers

PMID39130515
PMCPMC11316205

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.